| 谷瑞雪,邢 影,蔡 莉.ALK抑制剂治疗非小细胞肺癌的研究进展[J].中国肿瘤,2019,28(2):126-131. |
| ALK抑制剂治疗非小细胞肺癌的研究进展 |
| Progress in Treatment of Non-small Cell Lung Cancer with ALK Inhibitors |
| 投稿时间：2018-12-02 |
| DOI：10.11735/j.issn.1004-0242.2019.02.A010 |
|
 |
| 中文关键词: 肺肿瘤 ALK抑制剂 耐药 |
| 英文关键词:lung neoplasms ALK inhibitors resistance |
| 基金项目:国家自然科学基金面上项目（81572276） |
|
| 摘要点击次数: 6062 |
| 全文下载次数: 770 |
| 中文摘要: |
| 摘 要：肺癌是最常见的恶性肿瘤之一，且为全世界范围内肿瘤相关性死亡的首要原因，其中非小细胞肺癌（non-small cell lung cancer，NSCLC）约占肺癌总数的85%，预后较差。间变性淋巴瘤激酶（anaplastic lymphoma kinase，ALK）融合基因为促进肺癌进展的一个驱动基因，约2%~8%的NSCLC患者具有ALK融合基因，其对NSCLC的发生和发展至关重要。近年来靶向ALK融合基因已成为NSCLC治疗的前沿手段，第一、二、三代ALK酪氨酸激酶抑制剂（ALK-tyrosine kinase inhibitors，ALK-TKIs）治疗ALK阳性的NSCLC显示出较好的疗效，但仅在一定时间内对特定人群有效。因此规范应用ALK-TKIs、探讨耐药机制及应对不良反应等是临床面临的难题。本文关于这些问题的研究进展作一综述。 |
| 英文摘要: |
| Abstract：Lung cancer is one of the most common malignancies and remains the first leading cause of cancer-related mortality worldwide，and approximately 85% of all lung cancer cases are classified as non-small cell lung cancer (NSCLC)，the prognosis of which is poor. Anaplastic lymphoma kinase (ALK) fusion gene is a driver gene that promotes the progression of lung cancer. Approximately 2%~8% patients with NSCLC harbor ALK fusion gene，which is crucial to the occurrence and development of NSCLC. ALK fusion gene targeted therapy has become a frontier treatment for NSCLC in recent years. The first，second and third-generation ALK-tyrosine kinase inhibitors (ALK-TKIs) have robust efficacy in patients with ALK-positive NSCLC. Targeted treatments have been shown to be potential to control the disease for long time；however，it is still difficult to standardize the applications of ALK-TKIs，explore resistance mechanism and deal with adverse events. This article reviews the recent research progress of these issues. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |